Clovis Oncology, Inc. Quarterly Debt-to-equity in % from Q3 2014 to Q3 2022

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Clovis Oncology, Inc. quarterly Debt-to-equity history and growth rate from Q3 2014 to Q3 2022.
Clovis Oncology, Inc. Debt-to-equity for the quarter ending September 30, 2022 was -222 %, a 40.9% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q3 2022	-222	+153	+40.9%	Sep 30, 2022
Q2 2022	-255	+154	+37.6%	Jun 30, 2022
Q1 2022	-298	+173	+36.8%	Mar 31, 2022
Q4 2021	-325	+219	+40.2%	Dec 31, 2021
Q3 2021	-375	+168	+31%	Sep 30, 2021
Q2 2021	-409	+229	+35.9%	Jun 30, 2021
Q1 2021	-471	+268	+36.3%	Mar 31, 2021
Q4 2020	-544	+873	+61.6%	Dec 31, 2020
Q3 2020	-544	-3.38K	-119%	Sep 30, 2020
Q2 2020	-638	-1.3K	-197%	Jun 30, 2020
Q1 2020	-739	-1.1K	-307%	Mar 31, 2020
Q4 2019	-1.42K	-1.66K	-689%	Dec 31, 2019
Q3 2019	2.84K	+2.67K	+1586%	Sep 30, 2019
Q2 2019	659	+511	+345%	Jun 30, 2019
Q1 2019	357	+224	+168%	Mar 31, 2019
Q4 2018	241	+93.6	+63.6%	Dec 31, 2018
Q3 2018	168	-45.9	-21.4%	Sep 30, 2018
Q2 2018	148	-128	-46.4%	Jun 30, 2018
Q1 2018	133	-286	-68.3%	Mar 31, 2018
Q4 2017	147	-223	-60.3%	Dec 31, 2017
Q3 2017	214	-2.13	-0.98%	Sep 30, 2017
Q2 2017	276	+120	+76.8%	Jun 30, 2017
Q1 2017	419	+265	+172%	Mar 31, 2017
Q4 2016	370	+216	+139%	Dec 31, 2016
Q3 2016	216	+62.9	+41%	Sep 30, 2016
Q2 2016	156	+2.33	+1.51%	Jun 30, 2016
Q1 2016	154	+47.9	+45.2%	Mar 31, 2016
Q4 2015	155	+81.1	+110%	Dec 31, 2015
Q3 2015	153	+103	+204%	Sep 30, 2015
Q2 2015	154			Jun 30, 2015
Q1 2015	106			Mar 31, 2015
Q4 2014	73.6			Dec 31, 2014
Q3 2014	50.5			Sep 30, 2014

* An asterisk sign (*) next to the value indicates that the value is likely invalid.